Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

BACKGROUND: Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of treatment discontinuation of patients on paliperidone palmitat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Rui, Decuypere, Flore, Chevalier, Pierre, Desseilles, Martin, Lambert, Martin, Fakra, Eric, Wimmer, Antonie, Guillon, Pascal, Pype, Stefan, Godet, Annabelle, Borgmeier, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171957/
https://www.ncbi.nlm.nih.gov/pubmed/35672743
http://dx.doi.org/10.1186/s12888-022-03914-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171957/
https://www.ncbi.nlm.nih.gov/pubmed/35672743
http://dx.doi.org/10.1186/s12888-022-03914-2

Ejemplares similares